Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stake Lessened by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA trimmed its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 21.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 604,199 shares of the specialty pharmaceutical company's stock after selling 161,493 shares during the period. Massachusetts Financial Services Co. MA owned 1.87% of Collegium Pharmaceutical worth $17,310,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. New Age Alpha Advisors LLC bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at approximately $40,000. TD Private Client Wealth LLC lifted its position in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after buying an additional 483 shares during the last quarter. KBC Group NV boosted its holdings in shares of Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after buying an additional 982 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after buying an additional 316 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after acquiring an additional 642 shares during the period.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have recently commented on COLL shares. Piper Sandler lowered their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. StockNews.com upgraded Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday. Needham & Company LLC reissued a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of "Buy" and an average price target of $43.60.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock traded up $1.63 during trading hours on Friday, hitting $26.30. 617,106 shares of the company traded hands, compared to its average volume of 443,076. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29. The firm has a market cap of $845.07 million, a P/E ratio of 11.34 and a beta of 0.76. The firm's 50-day simple moving average is $29.14 and its two-hundred day simple moving average is $31.60. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Colleen Tupper sold 10,445 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total transaction of $313,454.45. Following the completion of the transaction, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the sale, the executive vice president now owns 124,421 shares of the company's stock, valued at $3,732,630. The trade was a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock valued at $2,334,994 over the last three months. Company insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.